Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives

References

• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188:2455-63
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol 2014;65:79-95
   PubMed Web of Science ®Google Scholar
• Nitti V, Rovner ES, Franks B, et al. Early experience with mirabegron: comparative persistence of mirabegron and tolterodine extended release in patients with overactive bladder. Poster session presented at: 39th Annual Meeting of the International Urogynecological Association; 2014 Jul 21-26; Washington DC (US)
   Google Scholar
• Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn 2015; doi:10.1002/nau.22943
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J 2015;9:343-50
   PubMed Web of Science ®Google Scholar
• Martan A, Mašata J, Švabík K, et al. [Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study]. Ceska Gynekol. 2015;80:244-8
   PubMedGoogle Scholar
• IMS Health. National Prescription Audit. Danbury, CT: IMS Health; 2014
   Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65
   PubMed Web of Science ®Google Scholar
• Edwards S, Karner C, Trevor N, et al. Mirabegron for the treatment of symptoms associated with overactive bladder. STA Report. London: BMJ-Technology Assessment Group; 2013
   Google Scholar
• Pfizer Labs. Toviaz prescribing information. New York, NY: Pfizer Labs; 2014
   Google Scholar
• TEVA Pharmaceuticals USA Inc. Oxybutynin prescribing information. Sellersville, PA: TEVA Pharmaceuticals USA Inc.; 2013
   Google Scholar
• Astellas Pharma US, Inc. VESIcare prescribing information. Northbrook, IL: Astellas Pharma US, Inc.; 2012
   Google Scholar
• Pfizer. Detrol LA prescribing information. New York, NY: Pfizer; 2012
   Google Scholar
• Pfizer. Detrol tolerodine tartrate tablets. New York, NY: Pfizer; 2012
   Google Scholar
• Allergan, Inc. Sanctura prescribing information. Irvine, CA: Allergan, Inc.; 2012
   Google Scholar
• Janssen Pharmaceuticals. Ditropan XL prescribing information. Titusville, NJ: Janssen Pharmaceuticals; 2015
   Google Scholar
• Astellas Pharma US, Inc. Myrbetriq® (mirabegron) extended-release tablets. Northbrook, IL: Astellas Pharma US, Inc.; 2013
   Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol 2014;21:960-7
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand 2013;92:1208-15
   PubMed Web of Science ®Google Scholar
• Aging Brain Program of the Indiana University Center for Aging Research. Anticholinergic Cognitive Burden Scale 2012 Update. Indianapolis, IN: Aging Brain Program of the Indiana University Center for Aging Research; 2012
   Google Scholar
• Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol 2013;189:210-16
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Hansen RN, Dmochowski RR, et al. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther 2013;35:414-24
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. 2014 CMS Statistics. Baltimore, MD: US Department of Health and Human Services; 2015
   Google Scholar
• U.S. Census Bureau. Current Population Survey, Annual Social and Economic Supplement, 2012. [Internet]. Washington, DC: U.S. Census Bureau, 2013. https://www.census.gov/population/age/data/2012comp.html. Accessed October 23, 2015
   Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011;29:35-49
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183:1438-43
   PubMed Web of Science ®Google Scholar
• Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 2016;35:246-51
   Web of Science ®Google Scholar
• Ivanova JI, Hayes-Larson E, Sorg RA, et al. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. J Med Econ 2014;17:741-50
   PubMedGoogle Scholar
• Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-56
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzman S, Errando-Smet C, Trocio J, et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol 2011;11:9
   PubMed Web of Science ®Google Scholar
• Campbell N, Perkins A, Bradt P, et al. Relationship between anticholinergic burden, cognitive impairment and healthcare utilization. Poster session presented at: 2015 American Society of Consultant Pharmacists Annual Meeting; 2015 Oct 30 – Nov 1; Las Vegas NV (US)
   Google Scholar
• Hall KS, Gao S, Emsley CL, et al. Community screening interview for dementia (CSI “D”); performance in five disparate study sites. Int J Geriatr Psychiatry 2000;15:521-31
   PubMed Web of Science ®Google Scholar
• Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-702
   PubMed Web of Science ®Google Scholar
• Caldwell N, Srebotnjak T, Wang T, et al. “How much will I get charged for this?” Patient charges for top ten diagnoses in the emergency department. PLoS One 2013;8:e55491
   PubMed Web of Science ®Google Scholar
• Avalere Health LLC. Aggregate Hospital Payment-to-cost Ratios for Private Payers, Medicare and Medicaid, 1993-2013. Trendwatch Chartbook 2015. Washington, DC: American Hospital Association; 2015
   Google Scholar
• Bureau of Labor Statistics. Consumer Price Index – All Urban Consumers. Medical Care [Internet]. Washington, DC: Bureau of Labor Statistics, 2016. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed January 5, 2016
   Google Scholar
• Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002;8:343-52
   PubMedGoogle Scholar
• Micromedex. Red Book Online. Accessed through Micromedex 2.0 [Internet]. Ann Arbor, MI: Micromedex; 2016
   Google Scholar
• Desroziers K, Aballéa S, Maman K, et al. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health Qual Life Outcomes 2013;11:200
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84-98
   PubMed Web of Science ®Google Scholar
• Valenstein M, Vijan S, Zeber JE, et al. The cost-utility of screening for depression in primary care. Ann Intern Med 2001;134:345-60
   PubMed Web of Science ®Google Scholar
• Lee BY, Bailey RR, Smith KJ, et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol 2010;31:598-606
   PubMed Web of Science ®Google Scholar
• Djalalov S, Yong J, Beca J, et al. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. Mol Diagn Ther 2012;16:389-99
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• AGS Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia. a prospective cohort study. JAMA Intern Med 2015;175:401-7
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43:604-15
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011;59:1477-83
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005;25:511-19
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-S9
   PubMed Web of Science ®Google Scholar
• Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2009;12:159-66
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005;14:849-55
   PubMed Web of Science ®Google Scholar
• Wu JM, Siddiqui NY, Amundsen CL, et al. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181:2181-6
   PubMed Web of Science ®Google Scholar
• Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519-27
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572-80
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-78
   PubMedGoogle Scholar